Summary

Report Overview
The Global Closed System Drug Transfer Devices Market reached US$ 1.25 billion in 2023 and is expected to reach US$ 4.37 billion by 2031 growing with a CAGR of 14.8% during the forecast period 2024-2031.
A closed system drug transfer device (CSTD) is a specialized medical equipment designed to safely transfer hazardous drugs by preventing the introduction of external contaminants into the system and blocking the release of hazardous drug substances or vapors outside the system.
The primary purpose of CSTDs is to establish a secure environment that significantly reduces the risk of exposure to dangerous substances. Exposure to these hazardous drugs can have severe health consequences for healthcare professionals and patients, including skin irritation, reproductive issues, and even cancer. By creating a closed system, CSTDs play a crucial role in safeguarding the well-being of everyone involved in the handling of these potent medications.
CSTDs generally follow one of two design concepts: physical barrier CSTDs and air cleaning CSTDs. The physical barrier CSTD uses mechanical means to block the escape of drug vapors, aerosols, and liquids into the surrounding environment. They also prevent the intake of contaminants from the environment into the sterile drug pathway. The physical barrier prevents direct contact between the hazardous drug and the environment or healthcare worker. It creates an impenetrable boundary to contain the drug and maintain sterility.
Another one is the air cleaning CSTDs use filtration technology to remove drug contaminants from the airflow, preventing their release into the environment. They also filter incoming air to remove environmental contaminants before they can enter the sterile drug pathway.
Both physical barrier and air-cleaning CSTDs are designed to achieve the same goal of protecting healthcare workers and the environment from exposure to hazardous drugs while preserving the sterility of the drug pathway. The choice between the two depends on factors like drug properties, facility layout, and user preference. When used properly, CSTDs significantly reduce the risks associated with handling hazardous medications.
Market Dynamics: Drivers
Rising prevalence of cancer and technological advancements
The demand for the global closed system drug transfer devices (CSDTs) market is driven by multiple factors. One of the primary factors is the rising prevalence of cancer and technological advancements. The global incidence of cancer is increasing rapidly, leading to a demand for chemotherapy and other hazardous medications.
Utilizing closed system drug transfer devices (CSTDs) is essential for protecting healthcare workers from occupational exposure to hazardous drugs. These devices are specifically engineered to reduce the risks linked to handling powerful medications, especially chemotherapy drugs, which can present serious health threats if healthcare personnel are unintentionally exposed.
As per WHO data in February 2024, in 2022, approximately 20 million new cancer cases were reported globally, resulting in nearly 9.7 million deaths. The most prevalent types of cancer that year included lung cancer, with 2.5 million cases (12.4% of all cancers), breast cancer at 2.3 million cases (11.6%), and colorectal cancer with 1.9 million cases (9.6%).
Lung cancer was the leading cause of cancer-related deaths, accounting for about 1.8 million fatalities (18.7%), followed by colorectal cancer with 900,000 deaths (9.3%) and liver cancer with 760,000 deaths (7.8%). Projections indicate that by 2050, the number of cancer cases could rise to 35 million, primarily due to population growth. Consequently, the rise in cancer cases demands the fueling of the need for closed system drug transfer devices (CSTDs) to facilitate the safe handling of these powerful drugs.
Moreover, innovations in closed system drug transfer device (CSTD) technology, such as the introduction of needle-free systems and enhanced sealing mechanisms, significantly improve usability and safety, thereby driving their adoption in healthcare settings.
In addition, key players in the industry's technological advancements, awareness programs, and key developments are driving the market growth. For instance, in September 2022, during the Formulation UK 2021 event organized by Oxford Global, Héloïse Audat, Drug Product Team Leader for Biologics Drug Product Development at Sanofi, presented an insightful overview of Sanofi's methods for evaluating closed system drug transfer devices (CSTDs). The first regulations on CSTDs came around 2004, intending to protect healthcare workers from the risk of systematic contact with hazardous drugs.
Similarly, BD introduced the Hazardous Drug Surface Contamination Monitoring Program is a comprehensive end-to-end solution designed to help healthcare facilities assess their current practices, develop an effective testing plan, and implement a sustainable monitoring program for hazardous drug surface contamination. This program aims to protect healthcare workers from potential exposure to hazardous drugs during preparation and administration.
Also, in March 2022, Simplivia Healthcare Ltd., a prominent global developer of medical devices, announced the upcoming release of Chemfort, a new closed system transfer device (CSTD). This device is designed specifically to enhance safety for healthcare professionals involved in the preparation and administration of hazardous drugs.
Restraints
Factors such as the high cost of implementation of CSTDs, regulatory challenges, and lack of awareness among individuals, are expected to hamper the market.
Market Segment Analysis
The global closed system drug transfer devices (CSDTs) market is segmented based on type, component, closing mechanism, technology, end-user, and region.
The needleless system segment accounted for approximately 74.3% of the global closed system drug transfer devices (CSDTs) market share
The needleless system segment is expected to hold the largest market share over the forecast period. Needleless systems are specifically designed to prevent needle stick injuries, a significant hazard for healthcare workers who handle hazardous drugs. These systems eliminate the need for traditional needles, thereby reducing the risk of accidental exposure to toxic substances.
Moreover, key players in the industry introducing innovative devices & launches help to drive this segment's growth in the market. For instance, ICU Medical, Inc. introduced the chemo-lock closed system transfer device (CSTD) utilizes a mechanically and microbiologically closed, needle-free design to prevent the escape of hazardous drug vapors and maintain the sterility of the drug during compounding and administration.
Similarly, Yukon Medical introduced the Arisure closed system transfer device (CSTD) is designed to protect healthcare workers from exposure to hazardous drug vapors during the compounding, transportation, and administration of chemotherapy and other hazardous medications. The Arisure CSTD utilizes a needle-free, luer lock connection system that is intuitive and easy to use. This eliminates the risk of needlestick injuries compared to traditional needle-based systems. The luer lock connections form a secure, airtight seal when connecting vials, syringes, and IV bags.
Also, in November 2023, BD (Becton, Dickinson and Company) launched a new needle-free blood draw technology called the PIVO Pro, designed to enhance patient care and support the company's vision of a "One-Stick Hospital Stay." This innovative device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is the first to offer compatibility with integrated and long peripheral IV catheters, including the Nexiva Closed IV Catheter System with NearPort IV Access.
Market Geographical Analysis
North America accounted for approximately 45.2% of the global closed system drug transfer devices (CSDTs) market share
North America region is expected to hold the largest market share over the forecast period owing to the increasing number of cancer cases in North America is a significant driver for the closed system drug transfer devices (CSTDs) market. As more patients require chemotherapy and other hazardous drug treatments, the a demand for safe handling solutions like CSTDs.
As per the American Cancer Society, in 2022, it was estimated that there would be approximately 1.9 million new cancer cases diagnosed and around 609,360 cancer-related deaths in the United States. The significant burden of cancer demand for closed system drug transfer devices (CSDTs) market.
In this region, a major number of key player's presence, technological advancements, product launches & approvals, well-advanced healthcare infrastructure, and growing oncology drug approvals are driving this market growth.
For instance, in September 2023, EQUASHIELD, a leading provider of closed system transfer devices (CSTDs) and automated pharmacy compounding solutions, has been recognized as the most used device for hazardous drug preparation and administration for five consecutive years by Pharmacy Purchasing & Products magazine. This remarkable achievement underscores EQUASHIELD's dedication to enhancing safety and efficiency in healthcare settings.
Similarly, in December 2023, West Pharmaceutical Services, Inc. a global leader in innovative solutions for injectable drug administration systems, announced FDA 510(k) clearance and launch of its Vial2Bag Advanced 13mm admixture device.
Also, in December 2021, B. Braun Medical Inc. announced the launch of the OnGuard 2 Closed System Transfer Device (CSTD) in the United States, which represents an advancement over its predecessor, the original OnGuard model. This new device incorporates several enhancements aimed at improving usability and safety for healthcare professionals handling hazardous drugs.
Market Segmentation
By Type
Membrane-to-Membrane Systems
Needleless Systems
By Component
Vial Access Devices
Syringe Safety Devices
Bag Spikes
Male and Female Luer Components
By Closing Mechanism
Click-to-Lock Systems
Luer-Lock Systems
Push-to-Turn
Color-to-Color Systems
By Technology
Diaphragm-Based Devices
Air Filtration Devices
By End-User
Hospitals
Oncology Clinics and Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the closed system drug transfer devices (CSDTs) market include BD, ICU Medical, Inc., EQUASHIELD, B. Braun Medical Inc., Yukon Medical, Simplivia, West Pharmaceutical Services, Inc., Baxter International Inc., JMS Co.Ltd., and Corning Incorporated among others.
Key Developments
In April 2023, EQUASHIELD, a leading provider of closed system transfer devices (CSTDs) for hazardous drugs, announced that its EQUASHIELD Syringe Unit has received FDA clearance for full-volume use. This means the system's closed Syringe Unit prevents intended and unintended syringe plunger detachment and can be used safely up to its maximal nominal volume when handling hazardous drugs.
Why Purchase the Report?
To visualize the global closed system drug transfer devices (CSDTs) market segmentation based on type, component, closing mechanism, technology, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the closed system drug transfer devices (CSDTs) market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.
The global closed system drug transfer devices (CSDTs) market report would provide approximately 78 tables, 72 figures, and 184 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Component
3.3. Snippet by Closing Mechanism
3.4. Snippet by Technology
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Cancer and Technological Advancements
4.1.2. Restraints
4.1.2.1. The High Cost of Implementation of CSTDs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Membrane-to-Membrane Systems *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Needleless Systems
7. By Component
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
7.1.2. Market Attractiveness Index, By Component
7.2. Vial Access Devices *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Syringe Safety Devices
7.4. Bag Spikes
7.5. Male and Female Luer Components
8. By Closing Mechanism
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
8.1.2. Market Attractiveness Index, By Closing Mechanism
8.2. Click-to-Lock Systems*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Luer-Lock Systems
8.4. Push-to-Turn
8.5. Color-to-Color Systems
9. By Technology
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. Diaphragm-Based Devices *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Air Filtration Devices
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Oncology Clinics and Centers
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. BD *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. ICU Medical, Inc.
13.3. EQUASHIELD
13.4. B. Braun Medical Inc.
13.5. Yukon Medical
13.6. Simplivia
13.7. West Pharmaceutical Services, Inc.
13.8. Baxter International Inc.
13.9. JMS Co.Ltd.
13.10. Corning Incorporated (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us